Abstract
Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have